Promising Results With NAD Supplementation in Rare Diseases With Premature Aging and DNA Damage.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic reasoning, animal models, and preliminary human data without systematic review criteria
PubMed 41436848 · doi:10.1111/acel.70319
What was done
This review synthesized mechanistic literature, animal model data, and emerging human findings regarding nicotinamide adenine dinucleotide (NAD) supplementation. It focused on the role of NAD depletion, poly-ADP-ribose polymerase (PARP1) hyperactivation (hyperparylation), and mitochondrial dysfunction in rare genetic premature aging disorders driven by defective DNA repair mechanisms.
What was found
The abstract reports no quantitative data, effect sizes, or specific sample sizes. It qualitatively describes that NAD supplementation improved DNA repair capacity and mitochondrial function in model systems and emerging human studies of premature aging disorders characterized by PARP hyperactivation.
Why it matters
The paper outlines a mechanistic rationale explaining variable clinical trial responses to NAD supplementation, suggesting that patients with high NAD depletion from DNA damage and PARP hyperactivation represent an optimal target population.
Limits
As a narrative review, it presents no systematic methodology, quantitative meta-analysis, or precise cohort data. Evidence relies substantially on preclinical disease models and unspecified emerging human reports.
Cited by
- supports Activation of PARP enzymes during DNA repair acts as a major consumer and drain on cellular NAD+ levels.